BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies and anti-HIV agents.

The company’s initial focus is on cancer, where it capitalizes on two recent scientific advances: the discovery that a complex natural product, bryostatin-1, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development.

BryoLogyx has licensed exclusive rights from Stanford University to the method’s use in the areas of cancer and HIV. Bryostatin-1, currently in preclinical development for use with immuno-oncology agents. Bryostatin-1 has an established safety profile based on prior clinical studies involving more than 1100 patients.